CONCOMITANT ADMINISTRATION OF LORNOXICAM AND ANTICOAGULANTS OR PLATELET AGGREGATION INHIBITORS MAY PROLONG THE BLEEDING TIME.-SULPHONYLUREAS: MAY INCREASE THE HYPOGLYCAEMIC EFFECT.-OTHER NON-STEROIDAL ANTI-INFLAMMATORY MEDICINES AND ASPIRIN: INCREASED RISK OF ADVERSE REACTIONS.-DIURETICS: DECREASED EFFICACY OF LOOP DIURETIC DRUGS; NSAIDS COUNTERACT THE DIURETIC EFFECT OF FUROSEMIDE.-ACE INHIBITORS: THE EFFECT OF THE ACE INHIBITOR MAY DECREASE AND THERE IS A RISK OF ACUTE RENAL INSUFFICIENCY.-LITHIUM: MIGHT LEAD TO AN INCREASE OF THE LITHIUM PEAK CONCENTRATION AND THUS TO A POSSIBLE INCREASE IN ADVERSE EVENTS. AVOID CONCOMITANT USE IF FREQUENT ANALYSIS OF LITHIUM CONCENTRATION IN PLASMA CANNOT BE PERFORMED.-METHOTREXATE: INCREASED SERUM CONCENTRATION OF HIGH DOSE METHOTREXATE; AVOID CONCOMITANT USE. SPECIAL CARE MUST BE TAKEN IF BOTH NSAIDS AND METHOTREXATE ARE ADMINISTERED WITHIN 24 HOURS.-CIMETIDINE: HIGHER PLASMA CONCENTRATIONS OF LORNOXICAM. (NO INTERACTION BETWEEN LORNOXICAM AND RANITIDINE, OR LORNOXICAM AND ANTACIDS HAS BEEN DEMONSTRATED).-DIGOXIN: DECREASED RENAL CLEARANCE OF DIGOXIN.-CYCLOSPORIN: INCREASED RENAL TOXICITY.LORNOXICAM HAS INTERACTIONS WITH KNOWN INDUCERS AND INHIBITORS OF CYP2C9 ISOENZYMES SUCH AS PHENYTOIN, AMIODARONE, MICONAZOLE, TRANYLCYPROMINE AND RIFAMPICIN.